Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.

CAPRISA, 2014.Abstract available in pdf

Randomized cross-sectional study to compare HIV-1 specific antibody and cytokine concentrations in female genital secretions obtained by menstrual cup and cervicovaginal lavage.

CAPRISA, 2015.Abstract available in pdf

Acceptability of early antiretroviral therapy among South African women.

CAPRISA, 2018.Abstract available in pdf

Comparison of cytokine concentrations and detection frequencies in genital fluid isolated from menstrual cups and CVLs in a randomised study.

<p>^aIQR: Interquartile range.</p><p>^bLLOD: Lower limit of detection.</p><p>^cMann-Whitney U tests were conducted to compare non-parametric unpaired data.</p><p>^dFisher’s exact tests were conducted to compare detection frequencies.</p><p>§Significant P-value after FDR multiple comparison adjustment.</p><p>Comparison of cytokine concentrations and detection frequencies in genital fluid isolated from menstrual cups and CVLs in a randomised study.</p

Comparison of median cytokine concentrations observed in genital fluid isolated from CVL, MC and matching subsequent CVL specimens in a randomised study.

<p>Cytokine concentrations were compared in genital fluid isolated from n = 19 MC- 4A and n = 20 randomized CVL, and n = 18 matching MC and subsequently-sampled CVL specimens- 4B. The concentrations of 48 cytokines [(regulatory ○; growth factor ✚; haematopoietic ✖; adaptive ◆; inflammatory ●)] were determined in each specimen by luminex technology and the median of each cytokine concentration was compared by Spearman rank correlation. Data are depicted on Log₁₀ scales. P-values <0.05 were considered significant.</p

Characteristics of participants overall, and stratified by study arm.

<p>Not all the study participants were tested for an STI or BV</p><p>Characteristics of participants overall, and stratified by study arm.</p

Comparison of total antibody (ng ml-1) in MCs (n = 19)- 3A, randomized CVL (n = 20) and matched post-MC CVLs (n = 18) [Log₁₀ MFI*dilution factor ng ml^-1 (MFI/total Ig)]- Correlation plots between total antibody in MCs and matched post MC CVLs- 3B.

<p>Correlation plots (Fig 3C–3F) of HIV specific activity in MCs (n = 18) and matched post-MC CVLs (n = 18) [Log₁₀ MFI*dilution factor ng ml^-1 (MFI/total Ig)] for gag p24- 3C, p66- 3D, gp41- 3E and gp120- 3F.</p

Schema of study design.

<p>Schema of study design.</p

HIV specific activity [Log₁₀ MFI*dilution factor ng ml^-1 (MFI/total Ig)] for gag p24- 2A, p66- 2B, gp41- 2C and gp120- 2D in MC (n = 19) and randomized CVL samples (n = 20).

<p>Limit of detection is shown as the dotted line on the figures.</p